

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| (51) International Patent Classification ⁶ : A61K 38/17 // C07K 14/47 | A1 | (11) International Publication Number: WO 97/17987 (43) International Publication Date: 22 May 1997 (22.05.97) |
| (21) International Application Number: PCT/US96/17940 | (81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). | |
| (22) International Filing Date: 8 November 1996 (08.11.96) | | |
| (30) Priority Data: 559,492 15 November 1995 (15.11.95) US | Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> | |
| (71) Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 N.E. Thirteenth Street, Oklahoma City, OK 73104 (US). | | |
| (72) Inventor: SIMS, PETER, J.; 6815 West Mendota Court, Mequon, WI 53092 (US). | | |
| (74) Agent: PABST, Patrea, L.; Arnall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US). | | |
| | | |
| (54) Title: C9 COMPLEMENT INHIBITOR | | |
| (57) Abstract | | |
| <p>Pharmaceutical compositions are designed based on the criticality of a portion of C9 for assembly of the C5b9 complex, which specifically modulate binding of CD59 to C9, either molecules structurally mimicking C9 amino acid residues 359 to 384 which bind to CD59 or molecules binding to C9 amino acid residues 359 to 384. Molecules which inhibit CD59 binding include peptides containing residues 359-384 which compete for binding with the other components of the C5b9 complex and anti-idiotypic antibodies immunoreactive with C9 amino acid residues 359 to 384. Molecules which prevent assembly of the C5b-9 complex include antibodies and antibody fragments immunoreactive with amino acid residues 359 to 384 of C9, peptides that bind to amino acid residues 359 to 384 of C9, and nucleotide molecules that bind to amino acid residues 359 to 384 of C9.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

C9 COMPLEMENT INHIBITOR

The present invention is generally in the area of inhibitors of complement-mediated inflammation, and is specifically directed to a compound inhibiting assembly of the C5b9 complex.

5 The U.S. government has certain rights in this invention by virtue of grant HL 36061 from the Heart, Lung and Blood Institute, National Institutes of Health to Peter J. Sims.

 The complement system is a complex interaction of plasma proteins and membrane cofactors which act in a multi-step, multi-protein
10 cascade sequence in conjunction with other immunological systems of the body to provide immunity from intrusion of foreign cells. Complement proteins represent up to about 10% of globulins in normal serum of man and other vertebrates.

 The classic complement pathway involves an initial antibody
15 recognition of, and binding to, an antigenic site (SA) on a target cell. This surface bound antibody subsequently reacts with the first component of complement, C1q, forming a C1-antibody complex with Ca^{++} , C1r, and C1s which is proteolytically active. C1s cleaves C2 and C4 into active components, C2a and C4a. The C4b,2a complex is an active
20 protease called C3 convertase, and acts to cleave C3 into C3a and C3b. C3b forms a complex with C4b,2a to produce C4b,2a,3b, which cleaves C5 into C5a and C5b. C5b combines with C6. The C5b,6 complex combines with C7 to form the ternary complex C5b,6,7. The C5b,6,7 complex binds C8 at the surface of the cell, which may develop functional
25 membrane lesions and undergo slow lysis. Upon binding of C9 to the C8 molecules in the C5b,6,7,8 complex, lysis of bacteria and other foreign cells is rapidly accelerated.

 The C5b-9 proteins of the human plasma complement system have been implicated in non-lytic stimulatory responses from certain human
30 vascular and blood cells. The capacity of C5b-9 to modify membrane permeability and to selectively alter ion conductance is thought to elicit these non-lytic responses from human cells. In the case of human blood

-2-

platelets and vascular endothelium, assembly of the C5b-9 complex initiates a transient and reversible depolarization of the plasma membrane potential, a rise in cytosolic Ca^{2+} , metabolic conversion of arachidonate to thromboxane or prostacyclin, and the activation of intracellular protein

5 kinases. In addition, human platelets exposed to C5b-9 undergo shape changes, secretory fusion of intracellular storage granules with plasma membrane, and the vesiculation of membrane components from the cell surface. Human endothelial cells exposed to the human C5b-9 proteins secrete high molecular weight multimers of the platelet adhesion protein, von Willebrand Factor (vWF), and the intracellular granule membrane
10 protein, $GMP140$, is translocated from the Weibel-Palade body to the endothelial surface. High molecular weight multimers of vWF have been implicated in the pathogenesis of vaso-occlusive platelet adherence to endothelium and cell surface $GMP140$ has been implicated in the
15 adherence of inflammatory leukocytes to endothelium.

These effects of complement proteins C5b-9 on platelet and endothelial cells alter the normal regulation of the enzymes of the plasma coagulation system at these cell surfaces. For example, the generation of platelet membrane microparticles by vesiculation is accompanied by the
20 exposure of membrane binding sites for coagulation factor Va. Binding of factor Va to the platelet plasma membrane and to these membrane microparticle sites initiates assembly of the prothrombinase enzyme complex. This complex in turn accelerates coagulation factor Xa activation of prothrombin to thrombin which promotes plasma clotting.
25 Similarly, C5b-9 binding to the endothelial cell results in the exposure of plasma membrane receptors for the prothrombinase complex, thereby accelerating the generation of thrombin from prothrombin at the endothelial surface.

This interaction between components of the complement and
30 coagulation systems at the surface of blood platelets and endothelium can generate inflammatory and chemotactic peptides at sites of vascular thrombus formation and may contribute to the altered hemostasis

-3-

associated with immune disease states. In addition, immune reactions affecting blood platelets and endothelium can lead to platelet aggregation, the secretion of proteolytic enzymes and vasoactive amines from platelet storage granules, and increase adherence of platelets and leukocytes to the

5 endothelial lining of blood vessels.

Assembly of the C5b-9 complex is normally limited in plasma by the amount of C5b generated by proteolysis of C5 to its biologically-active fragments C5b and C5a. In addition to plasmin and other plasma or cell-derived proteases, two enzymes of the complement system can
10 cleave C5 to C5a and C5b, the membrane-stabilized enzyme complexes C4b2a and C3bBb (C5-convertases). The activity of these two enzymes is normally inhibited on the surface of human blood and vascular membranes by the plasma membrane proteins, "membrane cofactor protein" (CD46), described by Lublin and Atkinson, Current Topics
15 Microbiol. Immunol. 153:123 (1989) and "decay-accelerating factor: (CD55), Medof, et al., J. Exp. Med. 160:1558 (1984).

Platelet and endothelial cell activation by C5b-9 also has ramifications in autoimmune disorders and other disease states. The importance of spontaneous complement activation and the resulting
20 exposure of platelets and endothelium to activated C5b-9 to the evolution of vaso-occlusive disease is underscored by consideration that a) leukocyte infiltration of the subendothelium, which is known to occur in regions of atheromatous degeneration and suggests localized generation of C5a at the vessel wall, is potentially catalyzed by adherent platelets and b) local
25 intravascular complement activation resulting in membrane deposition of C5b-9 complexes accompanies coronary vessel occlusion and may affect the ultimate extent of myocardial damage associated with infarction.

There is now considerable evidence that the human erythrocyte membrane as well as the plasma membranes of other human blood cells
30 and vascular endothelium are normally protected from these effects of complement by cell-surface proteins that specifically inhibit activation of the C5b-9 pore upon C9 binding to membrane C5b-8, as reported by

-4-

Holguin, M.H., et al., J. Clin. Invest. 84, 7-17 (1989); Sims, P.J., et al., J. Biol. Chem. 264, 19228-19235 (1989); Davies, A., et al., J. Exp. Med. 170, 637-654 (1989); Rollins, S.A., and Sims, P.J. J. Immunol. 144, 3478-3483 (1990); and Hamilton, K.K., et al., Blood 76, 2572-2577

5 (1990). Plasma membrane constituents reported to exhibit this activity include homologous restriction factor (HRF) (C8-binding protein), as described by Zalman, L.S., et al., Proc. Natl. Acad. Sci., U.S.A. 83, 6975-6979 (1986) and Schonermark, S., et al., J. Immunol. 136, 1772-1776 (1986), and the leukocyte antigen CD59, described by Sugita, Y., et
10 al., J. Biochem. (Tokyo) 104, 633-637 (1988); Hoiguin, M.H., et al., (1989); Sims, P.J., et al., (1989); Davies, A., (1989); Rollins, S.A., and Sims, P.J. (1990); and Hamilton, K.K., et al., (1990). Accumulated evidence suggest that these two proteins exhibit quite similar properties, including the following: both HRF and CD59 are tethered to the cell
15 surface by a glycolipid anchor, and are deleted from the membranes of the most hemolytically sensitive erythrocytes that arise in the stem cell disorder paroxysmal nocturnal hemoglobinuria; the activity of both inhibitors is species-restricted, showing selectivity for C8 and C9 that are derived from homologous (i.e. human) serum; and both HRF and CD59
20 appear to function by inhibiting the activation of C9, decreasing the incorporation of C9 into the membrane C5b-9 complex, and limiting propagation of the C9 homopolymer.

In U.S. Patent No. 5,136,916 to Sims and Wiedmer, Sims and Wiedmer disclose compositions and methods for use thereof relating to
25 polypeptides having the ability to act as an inhibitor of complement C5b-9 complex activity. The compositions contain CD59, active derivatives or fragments thereof which act to inhibit the activity of C5b-9, anti-idiotypic antibodies mimicking the action of the inhibitor proteins or antibodies against C7 or C9 which block the formation of the C5b-9 related
30 stimulatory responses of platelets and vascular endothelium of perfused organs and tissues, thereby preventing the C5b-9 initiated cell necrosis or stimulated secretion of proteolytic enzymes and the exposure of the

-5-

procoagulant membrane receptors during collection and *in vitro* storage. In one variation of this embodiment, the vascular endothelium of organs and tissues to be transplanted are treated with these compositions to protect these cells from complement activation after transplantation. In

5 another embodiment, immune disease states are treated by administering an effective amount of a C5b-9 inhibitor to suppress C5b-9 mediated platelet activation *in vivo*. Also disclosed are methods for the production of isolated polypeptides that are able to suppress complement C5b-9 mediated platelet and endothelial cell activation.

10 Human (hu)¹ CD59 antigen is a 18-21 kDa plasma membrane protein that functions as an inhibitor of the C5b-9 membrane attack complex (MAC) of hu complement. CD59 interacts with both the C8 and C9 components of MAC during its assembly at the cell surface, thereby inhibiting formation of the membrane-inserted C9 homopolymer
15 responsible for MAC cytolytic activity. This serves to protect hu blood and vascular cells from injury arising through activation of complement in plasma. CD59's inhibitory activity is dependent upon the species of origin of C8 and C9, with greatest inhibitory activity observed when C9 is from hu or other primates. By contrast, CD59 exerts little or no inhibitory
20 activity towards C8 or C9 of most other species, including rabbit (rb). Because the activity of CD59 is largely restricted to regulating hu C9, and the activity of analogous complement inhibitors expressed by cells of other species is likewise generally selective for homologous C9, xenotypic cells and tissue are particularly susceptible to complement-mediated
25 destruction due to unregulated activity of MAC. This phenomenon underlies hyperacute immune rejection after xenotransplantation.

Analysis of the physical association of CD59 with components of MAC suggested that separate binding sites for cD59 are contained within the α -chain of hu C8 and within hu C9. Within C9, this site(s) has been
30 mapped to between residues 334-415. The complement-inhibitory activity of CD59 is species-selective, and is most effective towards C9 derived from human or other primate plasma. The species-selective activity of

-6-

CD59 was recently used to map the segment of human C9 that is recognized by this MAC inhibitor, using recombinant rabbit/human C9 chimeras that retain lytic function within the MAC [Husler T, Lockert DH, Kaufman KM, Sodez JM, Sims PJ (1995). *J. Biol. Chem.*

5 270:3483-3486]. These experiments suggested that the CD59 recognition domain was contained between residues 334-415 in human C9.

It is apparent that additional or alternative inhibitors of the assembly of the C5b9 complex would be advantageous in inhibition of complement mediated inflammation. It is also clear that inhibitors which
10 are extremely specific and which are directed to the most critical regions involved in assembly or function of the complex would be most effective as inhibitors of complement mediated inflammation, with the least likelihood of non-specific side effects.

It is therefore an object of the present invention to provide a
15 method and materials for specifically inhibiting complement mediated inflammation.

It is another object of the present invention to provide a method and materials for determining the species specificity of C9 complement mediated activation and cytolysis.

20 Summary of the Invention

CD59 interacts with a segment of human C9 (hu C9) between residues 334-415, immediately C-terminal to the predicted membrane-inserting domain of C9. This segment of C9 contains a region of markedly divergent sequence when hu C9 is compared to C9 of other
25 species, with greatest divergence noted for the peptide segment contained within an internal Cys359-Cys384 disulfide in hu C9. In order to determine whether sequence contained in this peptide loop represents a hu C9-specific motif that is selectively recognized by CD59, CD59's inhibitory activity toward various full-length C9 chimeras containing hu-
30 unique or rabbit (rb)-unique sequence spanning this segment of the C9 polypeptide were analyzed. These experiments revealed that substitution

-7-

of hu residues 359-391 into otherwise rb C9 yielded a chimera indistinguishable from hu C9 in its regulation by CD59. C9 chimeras generated by substitution of hu C9 sequence flanking either side of residues 359-391 into rb C9 showed no consistent increase in inhibition

5 by CD59. This indicates that only residues contained between 359-391 of hu C9 are directly recognized by CD59. Moreover, truncation of the segment of hu C9 sequence in chimeric rb C9 from 359-391 to the putative recognition loop of hu 359-384 was accompanied by approximately 35% reduction of CD59 inhibitory function. Further,
10 CD59 specifically bound to a synthetic peptide corresponding to residues 359-384 of hu C9. IgG (Fab) specific for the hu C9 359-384 peptide inhibited the hemolytic activity of hu C9 (but not rb C9) in a manner analogous to CD59.

Pharmaceutical compositions are designed based on the criticality
15 of this portion of C9 for assembly of the C5b9 complex which specifically modulate binding of CD59 to C9, either molecules structurally mimicking C9 amino acid residues 359 to 384 which bind to CD59 or molecules binding to C9 amino acid residues 359 to 384. Molecules which inhibit CD59 binding include peptides containing residues 359-384 which
20 compete for binding with the other components of the C5b9 complex and anti-idiotypic antibodies immunoreactive with C9 amino acid residues 359 to 384. Molecules which prevent assembly of the C5b-9 complex include antibodies and antibody fragments immunoreactive with amino acid
25 residues 359 to 384 of C9, peptides that bind to amino acid residues 359 to 384 of C9, and nucleotide molecules that bind to amino acid residues 359 to 384 of C9.

Brief Description of the Drawings

Figure 1 is a plot of the inhibitory activity of CD59 towards hu/rb chimeras of complement C9. Bar graph (right panel) summarizes
30 combined results of all experiments measuring the inhibitory activity of CD59 towards recombinant hu/rb chimeras of C9. In each assay,

-8-

hemolytic titrations of C9 were performed against C5b-8 chE in the presence and absence of membrane CD59 and the percent reduction of hemolysis due to CD59 (*ordinate*) was determined, with normalization to that observed for hu C9 (100% inhibition). Error bars denote mean

5 +S.D., *parentheses* indicate number of independent experiments; *asterisks* (*) indicate significance ($p < 0.01$) when compared to rb C9; *pound signs* (#) indicate significance ($p < 0.01$) when compared to hu C9. To the left of each data bar, the protein assayed is depicted so as to designate those portions of the polypeptide containing hu C9 (*open*) or rb
10 C9 (*shaded*) sequence. Numbers above each construct indicate the junctional hu C9 residue at each transition between hu and rb protein sequence. Bars designated as *human* C9 and *rabbit* C9 denote recombinantly-expressed hu and rb C9, respectively. *Recombinant* C9 *chimeras* (designated #1-12) contain human (H) or rabbit (R) sequence
15 according to the deduced mature primary structure of hu and rb C9. In some C9 chimeras, the numbering appears discontinuous because of gaps in the alignment of the hu and rb sequences: 1, R1-338H334-415R425-536; 2, R1-363H359-538; 3, H1-357R363-536; 4, R1-363H359-415R425-536; 5, R1-363H359-391R401-536; 6, R1-400H392-415R425-536; 7, R1-
20 363H359-384R394-536; 8, H1-333R339-424H416-538; 9, H1-357R363-424H416-538; 10, H1-357R363-400H392-538; 11, H1-391R401-424H416-538; 12, H1-357R363-393H385-538.

Figure 2 is a schematic representation of the segment of hu C9 identified as containing the CD59 binding site, which according to the
25 proposed domain structure includes: thrombospondin type 1 (TS), LDL-receptor (LDLR), hinge (Hinge), membrane binding (MB), and epidermal growth factor precursor (EGFP) domains. *Shaded* segment indicates residues 334-415 of hu C9, spanning the putative CD59 binding site. The amino acid sequence of this peptide segment (Sequence ID No. 3) is given
30 below, and is shown in an alignment with rb C9 (Sequence ID No. 4) (alignment done for full-length polypeptides with the PALIGN program in PCGENE). *Asterisks* indicate sequence identity. Dotted lines indicate the

-9-

Cys 359/384 disulfide of hu C9 and the assumed corresponding internal disulfide in rb C9. Residue numbers refer to the mature proteins.

Figure 3 is a graph showing inhibitory activity of CD59 is unaffected by disruption of the Cys 359/384 disulfide. Recombinant hu

5 C9 was expressed with Cys→Ala mutation at either residue 384 or at both residues 359/384, and analyzed as described in Figure 1. Inhibitory activity of CD 59 towards the hemolytic function of each recombinant C9 is expressed as a percentage, relative to that measure for wild-type hu C9 (*ordinate*). *Error bars* denote mean +S.D., *n*, indicates number of
10 independent experiments; asterisks indicate significance (p.0.001) compared to hu C9. Hu C9 and rb C9 denote the wild type hu and rb proteins, respectively.

Figure 4 is a graph showing CD59 specifically binds hu C9 peptide 359-384. Microplates were coated with hu C9 peptide 359-384
15 coupled to BSA, and specific binding of biotin-CD59 determined in the presence of affinity-purified antibody against hu C9 residues 359-384 (●), or non-immune IgG (Δ) (IgG concentration indicated on *abscissa*). All data were corrected for nonspecific binding of CD59, determined in presence of 20-fold excess of unlabeled CD59. *Ordinate* denotes
20 absorbance at 405 nm, with correction for nonspecific background. *Error bars* denote mean +S.D. Data of a single experiment, representative of three so performed.

Figure 5A, 5B, 5C and 5D are graphs showing the inhibition of C9-dependent lysis by antibody against C9-peptide 359-384. Fab of
25 antibody against hu C9 peptide 359-384 (●) was tested for its capacity to inhibit the hemolytic activity of recombinant hu C9 (Figure 5A), hu/rb C9 chimera #7 (Figure 5B), recombinant rb C9 (Figure 5C), or hu/rb C9 chimera #12 (Figure 5D). Residues of human (H) and rabbit (R) sequence in each C9 chimera are indicated in Figure 1. Also shown is
30 data for non-immune antibody (Δ) (final concentrations indicated on *abscissa*). In all experiments, C5b-8 chE lacking CD59 served as target

-10-

cells and hemolysis measured with correction for nonspecific lysis. Data of single experiment, representative of three similar experiments.

Detailed Description of the Invention

I. C9 Peptide/CD59 C9 binding site Immunomodulators.

5 Peptide sequence in human complement protein C9 has been identified that contributes to the recognition of this protein by its naturally occurring inhibitor, CD59. CD59 is known to bind to neo-epitopes that become exposed in complement C8 and C9 during assembly of the cytolytic membrane attack complex of proteins C5b through C9. Through
10 this interaction, CD59 interrupts assembly of the C5b-9 complex, protecting the target cell from destruction by these complement proteins. Data demonstrates that antibody raised against this human C9-derived peptide sequence is functionally inhibitory towards the lytic activity of the human C5b-9 complex. This permits design of reagents directed
15 specifically at human C9 that mimic or inhibit the complement-inhibitory function of cell-surface CD59.

Compounds which bind CD59

As demonstrated by the following example, amino acid residues 359-384 of C9 are critical for binding of CD59 to C9, resulting in
20 inhibition of C5b-9 complex assembly. Peptides can be as short as 26 amino acids, less than forty amino acids, or less than 56 amino acids (359 to 415 amino acid peptide fragment of C9). Substitutions based on conserved sequence (rabbit for human, amino acids with similar structure and charge), presence or absence of a disulfide bond between the cysteine
25 residues, and elongation of the peptide through addition of supplemental amino acid sequence, were all shown not to significantly inhibit binding of CD59 to C9. Other derivatives that should also be active include covalently-cyclized derivatives, for example, disulfide-bonded and amide bonded peptides.

30 The data indicates that CD59 inhibits C9 through binding to human-specific residues contained within the Cys359-Cys384 disulfide loop of the

-11-

polypeptide. Optimal interaction of CD59 with this binding site in hu C9 appears to depend upon a few residues located immediately C-terminal to this segment of the protein. Although the specific role of this segment of C9 in membrane attack complex (MAC) assembly is unknown, the data

5 indicates that ligand binding to this site abrogates the lytic activity of the C5b-9 complex, implicating these residues in the conversion of C9 from solution monomer to membrane-embedded polymer. CD59 specifically binds a human C9-derived peptide corresponding to residues 359-384, and antibody (Fab) raised against this C9-derived peptide inhibits the lytic
10 activity of human MAC. Mutant human C9 in which Ala was substituted for Cys 359-384 was found to express normal lytic activity and to be fully inhibited by CD59. This suggests that the intrachain Cys359/Cys384 disulfide bond within C9 is not required to maintain the conformation of this segment of C9 for interaction with CD59. Other substitutions can
15 also be made without decreasing activity.

These compounds are effective as competitive inhibitors of CD59. Other compounds besides the peptides that can be used include anti-idiotypic antibodies and antibody fragments which bind to CD59, nucleotide molecules, and organic molecules that bind to the site on CD59
20 which binds amino acids 359-384 or 359 to 391. These can be identified using screening and computer assisted design, as described below.

Compounds which Inhibit C5b-9 Assembly

Data demonstrates that antibody raised against this human C9-derived peptide sequence is functionally inhibitory towards the lytic
25 activity of the human C5b-9 complex. Other compounds besides antibodies and antibody fragments which also bind to this peptide portion of C9, thereby preventing assembly of the C5b-9 complex, include peptides, nucleotide molecules, and organic molecules that bind to amino acids 359-384 or 359 to 391. These can be identified using screening and
30 computer assisted design, as described below.

-12-

Random generation of binding molecules.

Molecules with a given function, catalytic or ligand-binding, can be selected for from a complex mixture of random molecules in what has been referred to as "in vitro genetics" (Szostak, TIBS 19:89, 1992). One

5 synthesizes a large pool of molecules bearing random and defined sequences and subjects that complex mixture, for example, approximately 10^{15} individual sequences in 100 μ g of a 100 nucleotide RNA, to some selection and enrichment process. For example, by repeated cycles of affinity chromatography and PCR amplification of the molecules bound to
10 the ligand on the column, Ellington and Szostak (1990) estimated that 1 in 10^{10} RNA molecules folded in such a way as to bind a given ligand. DNA molecules with such ligand-binding behavior have been isolated (Ellington and Szostak, 1992; Bock et al, 1992).

Computer assisted drug design

15 Computer modeling technology allows visualization of the three-dimensional atomic structure of a selected molecule and the rational design of new compounds that will interact with the molecule. The three-dimensional construct typically depends on data from x-ray crystallographic analyses or NMR imaging of the selected molecule. The
20 molecular dynamics require force field data. The computer graphics systems enable prediction of how a new compound will link to the target molecule and allow experimental manipulation of the structures of the compound and target molecule to perfect binding specificity. Prediction of what the molecule-compound interaction will be when small changes
25 are made in one or both requires molecular mechanics software and computationally intensive computers, usually coupled with user-friendly, menu-driven interfaces between the molecular design program and the user.

Examples of molecular modelling systems are the CHARMM and
30 QUANTA programs, Polygen Corporation, Waltham, MA. CHARMM performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modelling and analysis of

-13-

molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

A number of articles review computer modeling of drugs

- 5 interactive with specific proteins, such as Rotivinen, et al., 1988 Acta Pharmaceutica Fennica 97, 159-166; Ripka, New Scientist 54-57 (June 16, 1988); McKinaly and Rossman, 1989 Annu. Rev. Pharmacol. Toxicol. 29, 111-122; Perry and Davies, QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc.
- 10 1989); Lewis and Dean, 1989 Proc. R. Soc. Lond. 236, 125-140 and 141-162; and, with respect to a model receptor for nucleic acid components, Askew, et al., 1989 J. Am. Chem. Soc. 111, 1082-1090. Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc., Pasadena, CA.,
- 15 Allelix, Inc., Mississauga, Ontario, Canada, and Hypercube, Inc., Cambridge, Ontario. Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to design of drugs specific to regions of DNA or RNA, once that region is identified.
- 20 Although described above with reference to design and generation of compounds which could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which are inhibitors or activators.
- 25 Nucleotide molecules which bind either CD59 or the C9 peptide can be generated *in vitro*, and then inserted into cells. Oligonucleotides can be synthesized on an automated synthesizer (e.g., Model 8700 automated synthesizer of Milligen-Bioscience, Burlington, MA or ABI Model 380B). (see, e.g., Offensperger et al., 1993 EMBO J. 12, 1257-
- 30 1262 (*in vivo* inhibition of duck hepatitis B viral replication and gene expression by antisense phosphorothioate oligodeoxynucleotides); Rosenberg et al., PCT WO 93/01286 (synthesis of sulfurthioate

-14-

oligonucleotides); Agrawal et al., 1988 Proc. Natl. Acad. Sci. USA 85, 7079-7083 (synthesis of antisense oligonucleoside phosphoramidates and phosphorothioates to inhibit replication of human immunodeficiency virus-1); Sarin et al., 1989 Proc. Natl. Acad. Sci. USA 85, 7448-7794

5 (synthesis of antisense methylphosphonate oligonucleotides); Shaw et al., 1991 Nucleic Acids Res 19, 747-750 (synthesis of 3' exonuclease-resistant oligonucleotides containing 3' terminal phosphoroamidate modifications). To reduce susceptibility to intracellular degradation, for example by 3' exonucleases, a free amine can be introduced to a 3' terminal hydroxyl
10 group of oligonucleotides without loss of sequence binding specificity (Orson et al., 1991). Furthermore, more stable triplexes are formed if any cytosines that may be present in the oligonucleotide are methylated, and also if an intercalating agent, such as an acridine derivative, is covalently attached to a 5' terminal phosphate (e.g., via a pentamethylene
15 bridge); again without loss of sequence specificity (Maher et al., (1989); Grigoriev et al., 1992).

Methods to produce or synthesize oligonucleotides are well known in the art. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see e.g., Sambrook et al.,
20 Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer (see also, Ikuta et al., in Ann. Rev. Biochem. 1984 53, 323-356 (phosphotriester and phosphite-triester methods); Narang et al., in Methods Enzymol., 65, 610-620 (1980) (phosphotriester
25 method).

Preparation of Peptides

Proteins can be expressed recombinantly and cleaved by enzymatic digest, expressed from a sequence encoding a peptide, or synthesized using standard techniques. It is a routine matter to make appropriate
30 peptides, test for binding, and then utilize. The peptides can be as short as twenty six amino acids in length and up to 57 amino acids, and are easily prepared by standard techniques. They can also be modified to

-15-

increase *in vivo* half-life, by chemical modification of the amino acids or by attachment to a carrier molecule or inert substrate.

The peptides can also be conjugated to a carrier protein such as ~~keyhole limpet hemocyanin by its N-terminal cysteine by standard~~
5 procedures such as the commercial Inject kit from Pierce Chemicals or expressed as a fusion protein, which may have increased efficacy. As noted above, the peptides can be prepared by proteolytic cleavage of C9, or, preferably, by synthetic means. These methods are known to those skilled in the art. An example is the solid phase synthesis described by J.
10 Merrifield, 1964 J. Am. Chem. Soc. 85, 2149, used in U.S. Patent No. 4,792,525, and described in U. S. Patent No. 4,244,946, wherein a protected alpha-amino acid is coupled to a suitable resin, to initiate synthesis of a peptide starting from the C-terminus of the peptide. Other methods of synthesis are described in U.S. Patent No. 4,305,872 and
15 4,316,891. These methods can be used to synthesize peptides having identical sequence to the receptor proteins described herein, or substitutions or additions of amino acids, which can be screened for activity as described above.

The peptide can also be administered as a pharmaceutically
20 acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid,
25 and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

Peptides containing cyclopropyl amino acids, or amino acids
30 derivatized in a similar fashion, can also be used. These peptides retain their original activity but have increased half-lives *in vivo*. Methods known for modifying amino acids, and their use, are known to those

-16-

skilled in the art, for example, as described in U.S. Patent No. 4,629,784 to Stammer.

The peptides are generally active when administered parenterally in amounts above about 1 $\mu\text{g/kg}$ of body weight. Based on extrapolation from other proteins, for treatment of most inflammatory disorders, the dosage range will be between 0.1 to 70 mg/kg of body weight. This dosage will be dependent, in part, on whether one or more peptides are administered. Based on studies with other peptide fragments blocking binding, the IC_{50} , the dose of peptide required to inhibit binding by 50%, ranges from about 50 μM to about 300 μM , depending on the peptides. These ranges are well within the effective concentrations for the *in vivo* administration of peptides, based on comparison with the RGD-containing peptides, described, for example, in U.S. Patent No. 4,792,525 to Ruoslahti, et al., used *in vivo* to alter cell attachment and phagocytosis.

15 *Antibodies*

Antibodies immunoreactive with the C9 peptide or an anti-idiotypic antibody to the antibodies immunoreactive with the C9 peptide can be prepared for use as described above.

In vivo Immunization of Animals

20 Animals such as mice may be immunized by administration of an amount of immunogen (either the C9 peptide or the antibody to the C9 peptide) effective to produce an immune response. Preferably a mouse is subcutaneously injected in the back with 100 micrograms of antigen, followed three weeks later with an intraperitoneal injection of 100
25 micrograms of cocaine immunogen with adjuvant, most preferably Freund's complete adjuvant. Additional intraperitoneal injections every two weeks with adjuvant, preferably Freund's incomplete adjuvant, may be necessary until the property titer in the mouse's blood is achieved. In order to use the mice for fusion and hybridoma production, a titer of at
30 least 1:5000 is preferred, and a titer of 1:100,000 or more is most preferred.

-17-

In vitro Immunization

The technique of *in vitro* immunization of human lymphocytes is frequently employed to generate a large variety of human monoclonal antibodies, ~~since deliberate *in vivo* priming of humans with many antigens~~

5 of interest is not feasible until approval by the Food and Drug Administration has been obtained. Techniques for *in vitro* immunization of human lymphocytes are well known to those skilled in the art. See, e.g., T. Inai, *et al.*, Histochemistry (Germany), 99(5):335-362 (May 1993); A. Mulder, *et al.*, Hum. Immunol., 36(3):186-192 (Mar. 1993);
10 H. Harada, *et al.*, J. Oral Pathol. Med. (Denmark), 22(4):145-152 (April 1993); N. Stauber, *et al.*, J. Immunol. Methods (Netherlands), 161(2):157-168 (May 26, 1993); and S. Venkateswaran, *et al.*, Hybridoma, 11(6) 729-739 (Dec. 1992). These techniques can be used to produce antigen-reactive human monoclonal antibodies, including antigen-
15 specific IgG, and IgM human monoclonal antibodies.

Humanization of Catalytic Antibodies

Because the methods for immunizing animals yield antibody which is not of human origin, the antibodies could elicit an adverse effect if administered to humans. Methods for "humanizing" antibodies, or
20 generating less immunogenic fragments of non-human antibodies, are well known. A humanized antibody is one in which only the antigen-recognized sites, or complementarity-determining hypervariable regions (CDRs) are of non-human origin, whereas all framework regions (FR) of variable domains are products of human genes. These "humanized"
25 antibodies present a less xenografic rejection stimulus when introduced to a human recipient.

To accomplish humanization of a selected mouse monoclonal antibody, the CDR grafting method described by Daugherty, *et al.*, Nucl. Acids Res., 19:2471-2476 (1991) may be used. Briefly, the variable
30 region DNA of a selected animal recombinant anti-idiotypic ScFv is sequenced by the method of Clackson, T., *et al.*, Nature, 352:624-688, 1991. Using this sequence, animal CDRs are distinguished from animal

-18-

framework regions (FR) based on locations of the CDRs in known sequences of animal variable genes. Kabat, H.A., *et al.*, Sequences of Proteins of Immunological Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987). Once the animal CDRs and FR

5 are identified, the CDRs are grafted onto human heavy chain variable region framework by the use of synthetic oligonucleotides and polymerase chain reaction (PCR) recombination. Codons for the animal heavy chain CDRs, as well as the available human heavy chain variable region framework, are built in four (each 100 bases long) oligonucleotides.
10 Using PCR, a grafted DNA sequence of 400 bases is formed that encodes for the recombinant animal CDR/human heavy chain FR protection.

The immunogenic stimulus presented by the monoclonal antibodies so produced may be further decreased by the use of Pharmacia's (Pharmacia LKB Biotechnology, Sweden) "Recombinant Phage Antibody System" (RPAS), which generates a single-chain Fv fragment (ScFv)
15 which incorporates the complete antigen-binding domain of the antibody. In the RPAS, antibody variable heavy and light chain genes are separately amplified from the hybridoma mRNA and cloned into an expression vector. The heavy and light chain domains are co-expressed on the same
20 polypeptide chain after joining with a short linker DNA which codes for a flexible peptide. This assembly generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody. Compared to the intact monoclonal antibody, the recombinant ScFv includes a considerably lower number of epitopes, and thereby
25 presents a much weaker immunogenic stimulus when injected into humans.

Pharmaceutical Compositions

The compounds described above are preferably administered in a pharmaceutically acceptable vehicle. Suitable pharmaceutical vehicles are
30 known to those skilled in the art. For parenteral administration, the compound will usually be dissolved or suspended in sterile water or saline. For enteral administration, the compound will be incorporated

-19-

into an inert carrier in tablet, liquid or capsular form. Suitable carriers may be starches or sugars and include lubricants, flavorings, binders, and other materials of the same nature. The compounds can also be administered locally by topical application of a solution, cream, gel, or polymeric material (for example, a Pluronic™, BASF).

Alternatively, the compound may be administered in liposomes or microspheres (or microparticles). Methods for preparing liposomes and microspheres for administration to a patient are known to those skilled in the art. U.S. Patent No. 4,789,734 describe methods for encapsulating biological materials in liposomes. Essentially, the material is dissolved in an aqueous solution, the appropriate phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary. A review of known methods is by G. Gregoriadis, Chapter 14. "Liposomes", Drug Carriers in Biology and Medicine pp. 287-341 (Academic Press, 1979). Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the bloodstream. Alternatively, the compound can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time, ranging from days to months. See, for example, U.S. Patent No. 4,906,474, 4,925,673, and 3,625,214.

II. Methods of Treatment

The effective amount of composition described above is that which achieves the desired effect: either to inhibit assembly of the C5b-9 complex by binding to C9 or to bind to the endogenous CD59 to prevent the CD59 from inhibiting assembly of the C5b-9 complex, thereby increasing complement mediated activation of cells.

Inhibition of CD59 is useful as an adjuvant for tumor therapy and as a contraceptive since it has been demonstrated that CD59 protects sperm from rejection by antibody and complement in the female genital tract and that CD59 expressed on human tumor cells protect these cells from complement mediated lysis.

-20-

Inhibition of C5b-9 complex assembly is useful for all disorders characterized by excessive complement activation or complement mediated cytotoxicity, including, for example, immune disorders and diseases such as immunovascularitis, rheumatoid arthritis, scleroderma, disseminated

5 intravascular coagulation, lupus, paroxysmal nocturnal hemoglobinuria, thrombotic thrombolytic purpura, vascular occlusion, reocclusion after surgery, coronary thrombosis, and myocardial infarction.

The present invention will be further understood by reference to the following studies.

10 **Example 1: Demonstration of role of a disulfide bonded peptide loop within hu C9 in the species-selectivity of CD59.**

EXPERIMENTAL PROCEDURES

Materials. Hu complement proteins C5b6, C7, C8, and C9, and hu erythrocyte membrane glycoprotein CD59 were purified and assayed as described by Davies, et al. *Immunol. Res.* 12, 258-275 (1993), Wiedmer and Sims, *J. Membr. Biol.* 84, 249-258 (1985), and Wiedmer and Sims, *J. Biol. Chem.* 260, 8014-8019 (1984). Hu C9 peptide 359-384 ([allyl-K]-CLGYHLDVSLAFSEISVGAEFNKDD-[allyl-C]), BSA-conjugated hu C9 peptide 359-384, and affinity-purified rb IgG against hu C9 peptide 20 359-384 were custom ordered from Quality Controlled Biochemicals (Hopkinton, MA). Full-length cDNA for hu C9 was a generous gift from Dr. J. Tschopp (University of Lausanne, Epalinges, Switzerland) and is described by Dupuis, et al., *Mol. Immunol.* 30, 95-100 (1993). Full length cDNA for rb C9 was isolated and cloned into pSVL as reported by 25 Husler, et al., *J. Biol. Chem.* 270, 3483-3486 (1995). Chicken erythrocytes (chE) were from Cocalico Biologics, Inc. (Reamstown, PA); COS-7 cells were from American Tissue Culture Collection (Rockville, MD); *E. coli* strain DH5 α and Opti-MEM I were from Life Technologies Inc. (Gaithersburg, MD), Dulbecco's Modified Eagle Medium was from 30 Mediatech Inc. (Herndon, VA), and heat-inactivated fetal bovine serum was from Biocell (Rancho Dominguez, CA). Oligonucleotides were

-21-

synthesized by the Molecular Biology Core Laboratories, Blood Research Institute.

Solutions. MBS: 150 mM NaCl, 10 mM MOPS, pH7.4; GVBS: 150 mM NaCl, 3.3 mM sodium barbital, 0.15 mM CaCl₂, 0.5 mM MgCl₂,

5 0.1 % (w/v) gelatin, pH 7.4; GVBE: 150 mM NaCl, 3.3 mM sodium barbital, 10 mM EDTA, 0.1 % (w/v) gelatin, pH 7.4.

Construction of chimeric C9 cDNA's. cDNA's coding for hu/rb C9 chimeras were constructed essentially as described by Husler, et al. (1995). In brief, regions of sequence identity were determined from the
10 aligned sequences of rb and hu C9, and used as junctions for chimeric cDNA construction. Based on these alignments, primers for PCR were designed to generate defined segments of rb and hu C9 cDNA's. Primers annealing to 5'-or 3'- untranslated sequence with added XbaI (5'-end) or SacI (3'-end) recognition sites were paired with chimeric primers (28-37
15 bp in length) and used to generate cDNA fragments that contained the desired overlapping sequence at either the 5'-or 3'-ends. These fragments were gel purified, mixed at a 1:1 molar ration, and used in a second amplification with primers located in the 5'-and 3'-untranslated region to produce full length chimeric C9 cDNA's. Fragments were cloned into
20 the XbaI/SacI sites of pSVL for mammalian expression. PCR fidelity was confirmed by sequencing 3'-coding sequence in each construct, starting from the stop codon and continuing through all junctions of rb and hu sequence. In certain cases, chimeric constructs were further modified by site directed mutagenesis.

25 Site Directed Mutagenesis. C9 cDNA in pSVL served as a template for site-directed mutagenesis using the *Chameleon* mutagenesis kit (Stratagene, La Jolla, CA). Mutagenesis was performed using 0.25 pmol of template plasmid, 25 pmol of mutagenic primer and 25 pmol of selection primer, the latter chosen to modify Sall, Scal, or XhoI
30 restriction sites unique to pSVL. The resulting mutagenized plasmids were subject to a minimum of two rounds of selection by restriction digest, and then transformed in *E. coli* XL1-Blue (Stratagene) for single

-22-

colony isolation and plasmid purification. In all cases, mutations were confirmed by double stranded sequencing of each purified plasmid.

Transfection of COS-7 cells. Plasmid DNA used in transfections was

~~obtained from purification over Qiagen-tips (Qiagen Inc., Chatsworth,~~

5 CA). COS-7 cells were transfected using DEAE-dextran, then cultured for 24h in Dulbecco's Modified Eagle Medium (Mediatech Inc., Herndon, VA) supplemented with 10% fetal bovine serum, after which this medium was replaced by Opti-MEM I (Life Technologies, Inc., Gaithersburg, MD). Cell supernatants were harvested after 48-65h, PMSF (1 mM),
10 benzamidine (1 mM) and EDTA (10 mM) were added and the supernatants concentrated at 4°C (Centricon 30, Amicon).

Immunoblotting. C9 in the COS-7 supernatants was analyzed by quantitative dot blotting using murine monoclonal antibody P9-2T as described by Husler, et al. (1995).

15 Biotin-CD59. CD59 was biotinylated by incubation (1 h, room temperature) with a 20-fold molar excess of NHS-LC-biotin in 10 mM MOPS, 0.1% Nonidet P-40, pH 9.0 followed by exhaustive dialysis against charcoal, as described by Chang, et al. *J. Biol. Chem.* 269, 26424-26430 (1994).

20 Analysis of the inhibitory function of CD 59 towards recombinant C9 constructs. Hemolytic activity of each C9 construct was assayed using as target cells chE that were reconstituted with purified hu CD59, as described by Husler, et al., (1995). chE were washed extensively and suspended in GVBS, and the membrane C5b67 complex assembled by
25 mixing cells (1.4×10^9 /ml) with C5b6 (13 μ g/ml) followed by addition of C7 (1 μ g/ml). After 10 min., the C5b67 chE were diluted to 1.4×10^8 /ml in GVBE and incubated (10 min. 37°C) with 0 or 750 ng/ml CD59. In each case, the final concentration of Nonidet P-40 was less than 0.002%(v/v). After washing in ice-cold GVBE, 2.8×10^8 of these
30 cells were incubated (37°C) in a total volume of 100 μ l with 1 ng rb C8 plus 0-50 ng of recombinant C9, serially diluted in Opti-MEM I. Hemolysis was determined after 30 minutes at 37°C, with correction for

-23-

nonspecific lysis, determined in the absence of C9. In each experiment, the inhibitory activity of CD59 towards each recombinant C9 construct was determined from the reduction in complement lysis of those cells reconstituted with CD59, versus the identically-treated cells omitting

5 CD59, measured at the midpoint of the C9 titration (i.e., 50% hemolysis). In order to directly compare results obtained in experiments performed on different days, data for each recombinant C9 construct were normalized to results obtained in each experiment with hu C9.

CD59 binding to hu C9 peptide 359-384. The specific binding of CD59
10 to hu C9-derived peptide 359-384 was measured by microtiter plate assay with biotin-CD59, according to modification of published methods of Chang, et al. (1994) and Husler, et al. (1995). Briefly, the BSA-peptide conjugate was adsorbed to 96 well polyvinyl microplates by overnight coating at 5 µg/ml in 0.1 M sodium bicarbonate, pH 8.5. After blocking
15 with 1% (w/v) BSA, wells were washed and incubated (4 hrs., 37°C) with 0.5-1 µg/ml biotin-CD59. After washing, the bound biotin-CD59 was detected with Vectastain (Vector Labs, Burlingame, CA), developed by addition of p-nitrophenyl phosphate (2 mg/ml) and optical density recorded at 405 nm (VMaxMicroplate Reader, Molecular Devices, Inc.).
20 In all experiments, correction was made for background adsorption of biotin-CD59 to BSA-coated wells (no peptide) and for nonspecific binding of biotin-CD59 to peptide, determined in the presence of a 20-fold excess of unlabeled CD59. As a positive control for specific binding, comparison was made in each experiment to wells coated with 2 µg/ml hu
25 C9. The capacity of monospecific antibody against hu C9 peptide 359-384 to compete specific binding of CD59 was determined by prior incubation of the BSA-peptide-coated wells with antibody (2 hrs., 0-100 µg/ml LgG) before addition of biotin-CD59.

Inhibition of MAC lysis by antibody against hu C9 peptide 359-384. The
30 capacity of antibody against hu C9 peptide 359-384 to inhibit MAC was determined by hemolytic assay, using the chE target cells described above, omitting CD59. In these experiments, 0-1 mg/ml Fab of antibody

-24-

against hu C9 peptide 359-384 (or, non-immune antibody control) was added with recombinant C9 (hu, rb, or chimeric), and complement-specific lysis determined.

RESULTS

5 C9 chimeras were constructed in which the segment of C9 corresponding to the putative CD59 binding site (residues 334-415 in hu C9; were interchanged between hu and rb C9. These chimeric proteins were then tested for hemolytic activity and for their sensitivity to inhibition by membrane CD59 (Figure 1). Substitution of hu C9 residues
10 334-415 into rb C9 (chimera #1) resulted in a protein that was indistinguishable from hu C9 in its sensitivity to inhibition by CD59. Conversely, when this same segment of hu C9 was replaced by the corresponding rb C9 sequence (chimera #8), the resulting chimera was indistinguishable from rb C9 and virtually unaffected by the presence of
15 membrane CD59. In these experiments, MAC was assembled using hu C5b67 and rb C8 so as to circumvent known inhibitory interaction of CD59 with hu C8 (Rollins, et al. *J. Immunol.* 146, 2345-2351 (1991), Ninomiya and Sims *J. Biol. Chem.* 267, 13675-13680 (1992).

As depicted in Figure 2, the segment of hu C9 shown to bind
20 CD59 is immediately C-terminal to the putative membrane-spanning domain of the protein, and corresponds to a segment of polypeptide exhibiting particularly low sequence conservation when hu C9 is aligned to C9 of rb or other non-primate species. The most prominent divergence of sequence occurs between two cysteines (Cys359-Cys384 in hu C9) that
25 are conserved in the hu and rb proteins. In hu C9, these cysteines have been shown to form an intrachain disulfide bond (below), as reported by Schaller, et al. *J. Protein Chem.* 13, 472-473 (1994).

In order to further localize the segment of hu C9 recognized by CD59 and to determine the specific contribution of residues spanning the
30 Cys359/384 disulfide, a series of hu/rb C9 chimeras was constructed by interchanging segments of corresponding hu and rb C9 sequences internal to residues 334-415. Each of these chimeric proteins was expressed and

-25-

analyzed for MAC hemolytic function, and for sensitivity to inhibition by membrane CD59. All resulting hu/rb C9 chimeras were functionally active as determined by hemolytic titration against chE containing membrane C5b-8. As shown in Figure 1, analysis of CD59-inhibitory

5 activity towards each of these proteins revealed inhibition of MAC lytic activity by CD59 was unaffected by replacement of all residues N-terminal to Cys359 of hu C9 with corresponding rb sequence (chimera #2), whereas replacement of all residues C-terminal to residue 358 of hu C9 with corresponding rb sequence (chimera #3) resulted in a protein
10 indistinguishable from rb C9 and only weakly inhibited by CD59.

Consistent with the results for chimeras #1-3, substitution of hu C9 residues 359-415 into the corresponding segment of otherwise rb C9 (chimera #4) resulted in a protein that was indistinguishable from hu C9, suggesting that this polypeptide segment of hu C9 (residues 359-415)
15 contains the binding site for CD59.

To further resolve the segment of hu C9 required for species-selective interaction with CD59, additional chimeras were constructed further truncating the segment of hu sequence substituted into rb C9 (chimera #5-7). Data for these chimeras revealed that whereas hu
20 residues 359-391 conferred full recognition by CD59 (chimera #5), hu C9 residues 392-415 failed to confer any recognition by CD59 (chimera #5), hu C9 residues 392-415 failed to confer any recognition by CD59 when inserted into an otherwise rb C9 (chimera #6). Truncation of the inserted segment of hu C9 sequence from 359-391 (chimera #5) to 359-384
25 (chimera #7) was accompanied by a small but significant reduction in inhibition of MAC lytic activity by CD59. These results imply that CD59 directly interacts with the segment of hu C9 contained between residues 359-391, with the peptide segment spanning the intrachain Cys359/384 disulfide substantially contributing to this interaction.

30 CD59's interaction with hu C9 was abrogated by replacement of sequence spanning this putative CD59 recognition domain with corresponding rb sequence (chimeras #8-12). Replacement of hu C9

-26-

residues 334-415 with corresponding rb sequence (chimera #8) completely eliminated hu-selective interaction with CD59, as anticipated for results obtained for the complementary construct, chimera #1. Nevertheless, when the segment of rb-derived sequence substituted into otherwise hu C9

5 was further truncated, the resulting chimeras (chimeras #9-12) retained a surprising degree of sensitivity to the inhibitory effects of CD59, characteristic of hu C9. Thus substitution of rb sequence for the residues internal to Cys359-384 of hu C9 (chimera #12) did not significantly diminish CD59's capacity to inhibit the lytic activity of C9, while C-

10 terminal extension of the segment of rb sequence to residue 415 (chimera #9) did not completely eliminate interaction with CD59. Taken together with results for chimeras #1-5, these data indicate that whereas hu C9 residues 359-391 alone are sufficient to confer recognition by CD59, segments of the polypeptide immediately flanking this segment

15 significantly contribute to the extent to which this binding site is expressed.

The Cys359/384 disulfide in hu C9 has recently been reported to be highly labile and subject to spontaneous reduction in the native protein, as reported Hatanaka, et al., *Biochim. Biophys. Acta Protein Struct. Mol. Enzymol.* 1209, 117-122 (1994). Since the data suggested that residues

20 internal to Cys359/384 contribute in-large-part to species-selective recognition by CD59, the extent to which the CD59 recognition site in C9 is affected by disruption of this bond was examined. Mutant hu C9 was expressed with Ala substitutions at Cys359 and Cys384 and tested for

25 hemolytic activity and for sensitivity to inhibition by CD59. As revealed by data of Figure 3, disruption of this disulfide bond did not significantly affect the hemolytic activity of the protein nor the capacity of CD59 to specifically inhibit C9 lytic activity. This suggests that the segment of hu C9 forming the CD59 binding site is either conformationally constrained

30 independent of the Cys359-384 disulfide, or, that this binding site is expressed in the primary structure of hu C9, independent of protein folding.

-27-

In order to confirm that the peptide segment spanning hu C9 359-384 can itself mediate interaction with CD59, this 26 residue peptide was synthesized, coupled to BSA, and analyzed for CD59 binding, using

~~biotin-CD59 conjugate in a micro-plate assay.~~ As demonstrated by Figure

5 4, biotin-CD59 specifically bound to C9 peptide 359-384, and this binding was inhibited by excess unlabeled CD59 or by antibody directed against the peptide.

CD59 is known to bind to C9 after C9 incorporates into the C5b-9 complex, and through this interaction inhibit propagation of membrane-
10 inserted C9 polymer, limiting lytic activity of MAC. In order to confirm the importance of the peptide segment recognized by CD59 to MAC assembly, Fab of antibody raised against the hu C9 peptide 359-384 was tested for its capacity to inhibit the hemolytic activity of the hu C5b-9 complex, under the same condition used to evaluate the inhibitory
15 function of CD59. As shown by the data of Figures 5A-D, this Fab inhibited hemolytic activity of hu C9 (Figure 5A) and C9 chimera #7 (representing rb C9 containing hu C9 residues 359-384, Figure 1, Figure 5B), but had no effect on the hemolytic activity of either rb C9 (Figure 5C) or chimera #12 (representing substitution of the corresponding
20 segment of rb C9 residues into hu C9; Figure 1, Figure 5D).

The experiments show that hu C9 residues 359-391 promote CD59 binding, and that this segment of hu C9 contributes to the species-selective regulation of MAC function, providing an initial clue to the structural motif(s) through which this inhibitor selectively regulates the
25 lytic activity of hu C5b-9 complex. These data further indicate that the capacity of CD59 to optimally interact with this segment of hu C9 is significantly influenced by residues immediately C-terminal to this segment of the C9 polypeptide.

Whereas the data establish that residues internal to Cys359-Cys384
30 contribute to recognition by CD59, the disulfide bond between these two Cys is apparently not required either for maintenance of C9's hemolytic activity within MAC, or, for normal regulation of that activity by

-28-

membrane CD59. These conclusions derived by Cys/Ala mutagenesis in recombinant hu C9 (Figure 3) are consistent with previous reports indicating: (i) the intrinsic liability of the Cys 359-384 disulfide in C9 purified from hu plasma, where spontaneous reduction of this bond did not appear to alter C9 hemolytic activity, and (ii) that a specific CD59 binding site is retained in reduced and carboxymethylated hu C9, in hu C9-derived peptide fragments, and can be demonstrated for *E. Coli* fusion proteins contains hu C9-derived sequence spanning residues 359-384. This suggests that the CD59 binding site expressed by this segment of hu C9 reflects interactions between amino acid side chains that do not require formation of the Cys 359/Cys 384 disulfide bond.

As noted above, chimeras generated by substituting limited segments of hu C9 into rb C9 revealed that the segment of hu C9 between 359-384 uniquely conferred recognition by CD59, and that this interaction was enhanced by C-terminal extension of hu sequence to residue 391 (cf. Chimeras #1-7; Figure 1). Surprisingly, chimeras generated by replacing these same segments of hu C9 with corresponding rb C9 sequence did not exhibit a complementary decrease in interaction with CD59, except when the segment of rb-derived sequence replaced in hu C9 residues spanning 334-415 (cf. Chimeras #8-12; Figure 1).

Sequence ID No. 1 sets forth the nucleotide sequence shown below. Sequence ID No. 5 sets forth the amino acid sequence shown below encoded by the first nucleotide shown through nucleotide 1681. Sequence ID No. 6 sets forth the amino acid sequence shown below encoded by nucleotides 1685 through 1699. Sequence ID No. 7 sets forth the amino acid sequence shown below encoded by nucleotides 1703 through 1770. Sequence ID No. 8 sets forth the amino acid sequence shown below encoded by nucleotides 1774 through 1834. Sequence ID No. 9 sets forth the amino acid sequence shown below encoded by nucleotides 1838 through 1846. Sequence ID No. 10 sets forth the amino acid sequence shown below encoded by nucleotides 1850 through 1870.

-29-

Sequence ID No. 11 sets forth the amino acid sequence shown below encoded by nucleotides 1874 through 2026.

Sequence ID No. 2 sets forth the nucleotide sequence shown below. ~~Sequence ID No. 12 sets forth the amino acid sequence shown~~

- 5 below encoded by the first nucleotide shown through nucleotide 1683. Sequence ID No. 13 sets forth the amino acid sequence shown below encoded by nucleotides 1687 through 1818. Sequence ID No. 14 sets forth the amino acid sequence shown below encoded by nucleotides 1822 through nucleotide 1911. Sequence ID No. 15 sets forth the amino acid
- 10 sequence shown below encoded by nucleotides 1915 through nucleotide 1947. Sequence ID No. 16 sets forth the amino acid sequence shown below encoded by nucleotides 1919 through nucleotide 2043.

-30-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Oklahoma Medical Research Foundation
- (ii) TITLE OF INVENTION: C9 Complement Inhibitor
- (iii) NUMBER OF SEQUENCES: 16
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: ~~Patrea L. Pabst~~
 - (B) STREET: 2800 One Atlantic Center, 1201 West Peachtree Street
 - (C) CITY: Atlanta
 - (D) STATE: Georgia
 - (E) COUNTRY: USA
 - (F) ZIP: 30309-3450
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/559,492
 - (B) FILING DATE: 15-NOV-1995
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Pabst, Patrea L.
 - (B) REGISTRATION NUMBER: 31,284
 - (C) REFERENCE/DOCKET NUMBER: OMRF154
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 404-873-8794
 - (B) TELEFAX: 404-873-8795

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2026 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | |
|--------------------------------------------------------------------|-----|
| CAGCATGTCA GCCTGCCGGA GCTTTGCAGT TGCAATCTGC ATTTTAGAAA TAAGCATCCT | 60 |
| CACAGCACAG TACACGACCA GTTATGACCC AGAGCTAACA GAAAGCAGTG GCTCTGCATC | 120 |
| ACACATAGAC TGCAGAAATGA GCCCCTGGAG TGAATGGTCA CAATGCGATC CTTGTCTCAG | 180 |
| ACAAATGTTT CGTTCAAGAA GCATTGAGGT CTTTGGACAA TTTAATGGGA AAAGATGCAC | 240 |
| CGACGCTGTG GGAGACAGAC GACAGTGTGT GCCCAGAGAG CCCTGTGAGG ATGCTGAGGA | 300 |
| TGACTGCGGA AATGACTTTC AATGCAGTAC AGGCAGATGC ATAAAGATGC GACTTCGGTG | 360 |
| TAATGGTGAC AATGACTGCG GAGACTTTTC AGATGAGGAT GATTGTGAAA GTGAGCCCCG | 420 |
| TCCCCCTGC AGAGACAGAG TGGTAGAAGA GTCTGAGCTG GCACGAACAG CAGGCTATGG | 480 |
| GATCAACATT TTAGGGATGG ATCCCCTAAG CACACCTTTT GACAATGAGT TCTACAATGG | 540 |
| ACTCTGTAAC CGGGATCGGG ATGGAAACAC TCTGACATAC TACCGAAGAC CTTGGAACGT | 600 |
| GGCTTCTTTG ATCTATGAAA CCAAAGGCGA GAAAAATTTT AGAACCGAAC ATTACGAAGA | 660 |
| ACAAATTGAA GCATTTAAAA GTATCATCCA AGAGAAGACA TCAAATTTTA ATGCAGCTAT | 720 |

-31-

| | | | | | | |
|-------------|--------------|------------|------------|------------|------------|------|
| ATCTCTAAAA | TTTACACCCA | CTGAAACAAA | TAAAGCTGAA | CAATGTTGTG | AGGAAACAGC | 780 |
| CTCCTCAATT | TCTTTACATG | GCAAGGGTAG | TTTTCGGTTT | TCATATTCCA | AAAATGAAAC | 840 |
| TTACCAACTA | TTTTTGTGTCAT | ATTCTTCAAA | GAAGGAAAAA | ATGTTTCTGC | ATGTGAAAGG | 900 |
| AGAAATTTCAT | CTGGGAAGAT | TTGTAATGAG | AAATCGCGAT | GTTGTGCTCA | CAACAACTTT | 960 |
| <hr/> | | | | | | |
| TGTGGATGAT | ATAAAAGCTT | TGCCAACTAC | CTATGAAAAG | GGAGAATATT | TTGCCTTTTT | 1020 |
| GGAAACCTAT | GGAACCTACT | ACAGTAGCTC | TGGGTCTCTA | GGAGGACTCT | ATGAACTAAT | 1080 |
| ATATGTTTTG | GATAAAGCTT | CCATGAAGCG | GAAAGGTGTT | GAACATAAAG | ACATAAAGAG | 1140 |
| ATGCCTTGGG | TATCATCTGG | ATGTATCTCT | GGCTTTCTCT | GAAATCTCTG | TTGGAGCTGA | 1200 |
| ATTTAATAAA | GATGATTGTG | TAAAGAGGGG | AGAGGGTAGA | GCTGTAAACA | TCACCAGTGA | 1260 |
| AAACCTCATA | GATGATGTTG | TTTCACTCAT | AAGAGGTGGA | ACCAGAAAAT | ATGCATTTGA | 1320 |
| ACTGAAAGAA | AAGCTTCTCC | GAGGAACCGT | GATTGATGTG | ACTGACTTTG | TCAACTGGGC | 1380 |
| CTCTTCCATA | AATGATGCTC | CTGTTCTCAT | TAGTCAAAAA | CTGTCTCCTA | TATATAATCT | 1440 |
| GGTTCCAGTG | AAAATGAAAA | ATGCACACCT | AAAGAAACAA | AACTTGAAAA | GAGCCATTGA | 1500 |
| AGACTATATC | AATGAATTTA | GTGTAAGAAA | ATGCCACACA | TGCCAAAATG | GAGGTACAGT | 1560 |
| GATTCTAATG | GATGGAAAGT | GTTTGTGTGC | CTGCCCATTG | AAATTTGAGG | GAATTGCCTG | 1620 |
| TGAAATCAGT | AAACAAAAAA | TTTCTGAAGG | ATTGCCAGCC | CTAGAGTTCC | CCAATGAAAA | 1680 |
| ATAGAGCTGT | TGGCTTCTCT | GAGCTCCAGT | GGAAGAAGAA | AACACTAGTA | CCTTCAGACT | 1740 |
| CCTACCCCTG | AAGATAATCT | TAGCTGCCAA | GTAAATAGCA | ACATGCTTCA | TGAAAATCCT | 1800 |
| ACCAACCTCT | GAAGTCTCTT | CTCTCTTAGG | TCTATAATTT | TTTTTTTAAT | TTTTCTTCCT | 1860 |
| TAAACTCCTG | TGATGTTTCC | ATTTTTTGTT | CCCTAATGAG | AAGTCAACAG | TGAAATACGC | 1920 |
| CAGAACTGCT | TTATCCCACG | GAAAATGCCA | ATCTCTTCTA | AAAAAAAACA | AAATTAAATT | 1980 |
| AAAAACAGAA | TGTTGGTTTA | AAAAACTTCA | AAGAAAAAAA | AAAAAA | | 2026 |

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2034 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-----|
| CTCGTGAGCA | GCATGGCCGC | CAGCCACAGC | TTCGCCTTTG | TGGTCTGCGT | TTTAGAAATC | 60 |
| GGTGCCCTGA | CGGCAGGACC | CACTCCCAGC | TATGTCCACG | AGCCGATACA | AAGGAGTGAC | 120 |
| CCTCTGCAGC | CCATAGACTG | CAGGATGAGC | CCATGGAGTG | AATGGTCGCA | CTGTGATCCT | 180 |
| TGTCTCAGGC | AAATGTTTTG | TTCAAGGAGC | ATCGAAGTCT | TTGGACAATT | TCATGGGAAA | 240 |
| AGTTGTGTGG | ATGCTCTGGG | CGACAGGCGA | GCGTGTATAC | CTACGGAGGC | ATGCCAAGAC | 300 |
| GCTGAGGAGG | ACTGTGAAAA | AGACGAATTT | CACTGTGGGA | CAGGCAGGTG | CATAAAGAGG | 360 |
| CGACTGCTGT | GTAATGGGGA | CAATGACTGC | GGAGACTTTT | CAGATGAGGA | TGACTGCGAA | 420 |

-32-

| | |
|------------------------------------------------------------------------------|----------------|
| ACGGAGCCCC GTCTTACCTG TCGCAACCGC GAGGTCCAAG AGTCGGAGCT GGCACGGACA | 480 |
| GCGGGCTATG GGATCAACAT TTTAGGGATG GATCCCCTAG CCACACCTTT TGACAACGAG | 540 |
| TACTACCACG GACTCTGTGA CCGTGTTTGG GATGGGAACA CTTTGACACA CTATCGAAAA | 600 |
| CCCTGGAATG TGGCTGTTTT GGCCTATGAA ACAAAAATTG ATAAAAATTT CAGAACTGAA | 660 |
| TACTATGAAG AACAGATGCA GGCATTCAAA AGTATCATTG AAGAAGAGAC ATCAAATTTT | 720 |
| AATGCAAATT TAGCTCTAAA ATTTACACCC ACCGAAGCAA AAGCAAGTAA GGCTGAAGAA | 780 |
| GCTTCTCCAA AAAACAAGTC TTTGGATGAT AATGATAAAG GTTCTCTGAG TAAATTTCAA | 840 |
| TTTTCGTATT CCAAAAATGA AACTTACCAA CTATTCCTGT CATATTCTTC ACAGAAGGAA | 900 |
| AAAATGTTTC TGCTTGTGAA AGGAATAATT CAACTGGGAA GATTTGTGAT GAAAAATCGG | 960 |
| GGTGTATATG TGACAAATAC CTTCTTGGAT GATATAAAAT CTCTGCCAAC TACCTATGAA | 1020 |
| AAAGGAGAAT ATTTTGCATT TTTGGAAACC TATGGAACCC ACTATAGTAG CTCTGGGTCT | 1080 |
| CTGGGAGGAC GCTATGAGCT AATTTATGTT TTGGATAAAG CTTCCATGAA GGAGAAAGGG | 1140 |
| ATTGAGCTGA ATGACATAAA GAAATGCCTT GGGTTTGA CTAGATTTATC TCTGAATATC | 1200 |
| CCTGGAATAA CTGCTGGGCT TTCGCTCACA GGACAAGCAA ATAAAAACAA TTGCTTAAAG | 1260 |
| AGTGGTCATG GTAATGCTGT AACATCACC AGGGCTAACC TCATAGATGA TGTGATTTCA | 1320 |
| CTCATAAGAG GAGGAACCCA AAAATTTGCG TTTGAATTGA AAGAAAAGCT TCTCACCAAA | 1380 |
| GCCAAGATGG TTGACGTGAC GGACTTTATC AATTGGGCCT CTTCTTAAG TGATGCTCCA | 1440 |
| GTGCTCATCA ATCAAAAAC GTCCCTATA TATAATCTGA TTCCTGTGAA AATAAAAGAT | 1500 |
| GCGCACCAAA AGAGACAGAA TCTGGAGAGA GGAATTGAAG ATTACATCAA TGAATTCAGC | 1560 |
| ACGAAAAAGT GCTCCCCCTG CAAAACGGA GGCACGAC TTCTGATGGA TGGCCAGTGT | 1620 |
| TTGTGTACCT GCGCGTTTAT GTTCGAGGGG ATTGCCTGTG AAATCTCAA ACGAAAACTG | 1680 |
| GCTTAAGGAT TGCCAGCCCC CACCCCAACC CCCCATAATG CAACTGTTGA GTTCCCTGAG | 1740 |
| CTCAAATGGA AGAAAAACAA CACCAGGACC TTCCAATGTA AGATCCTGCC CTGCCTGGAG | 1800 |
| ATAGTCCTTG CTGGCACATG AAAAGCAACA TGTTTCATGA AAACCCTACC AACCTCTGAA | 1860 |
| GCCTCGCTCT CTCTCTGGTC TGCAATGCCT GTTTTTCCCC ATAAACCCT GTAAATGTTTC | 1920 |
| CATTTTTATT TAATGAAGAG ACAGCCATGA GCTGTGCCAG AAGTGTTTTC TCCCACAGCC | 1980 |
| AATGCCAGCC TCTTGCTAAT AAAAGAAAAT AAAATTCAAA AAAAAAAAAA AAAA | 2034 |

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 82 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Tyr | Glu | Leu | Ile | Tyr | Val | Leu | Asp | Lys | Ala | Ser | Met | Lys | Arg | Lys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

-33-

Gly Val Glu Leu Lys Asp Ile Lys Arg Cys Leu Gly Tyr His Leu Asp
 20 25 30
 Val Ser Leu Ala Phe Ser Glu Ile Ser Val Gly Ala Glu Phe Asn Lys
 35 40 45
 Asp Asp Cys Val Lys Arg Gly Glu Gly Arg Ala Val Asn Ile Thr Ser
 50 55 60

Glu Asn Leu Ile Asp Asp Val Val Ser Leu Ile Arg Gly Gly Thr Arg
 65 70 75 80
 Lys Tyr

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 86 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Arg Tyr Glu Leu Ile Tyr Val Leu Asp Lys Ala Ser Met Lys Glu Lys
 1 5 10 15
 Gly Ile Glu Leu Asn Asp Ile Lys Lys Cys Leu Gly Phe Asp Leu Asp
 20 25 30
 Leu Ser Leu Asn Ile Pro Gly Lys Ser Ala Gly Leu Ser Leu Thr Gly
 35 40 45
 Gln Ala Asn Lys Asn Asn Cys Leu Lys Ser Gly His Gly Asn Ala Val
 50 55 60
 Asn Ile Thr Arg Ala Asn Leu Ile Asp Asp Val Ile Ser Leu Ile Arg
 65 70 75 80
 Gly Gly Thr Gln Lys Phe
 85

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 560 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Met Ser Ala Cys Arg Ser Phe Ala Val Ala Ile Cys Ile Leu Glu
 1 5 10 15
 Ile Ser Ile Leu Thr Ala Gln Tyr Thr Thr Ser Tyr Asp Pro Glu Leu
 20 25 30
 Thr Glu Ser Ser Gly Ser Ala Ser His Ile Asp Cys Arg Met Ser Pro
 35 40 45
 Trp Ser Glu Trp Ser Gln Cys Asp Pro Cys Leu Arg Gln Met Phe Arg
 50 55 60
 Ser Arg Ser Ile Glu Val Phe Gly Gln Phe Asn Gly Lys Arg Cys Thr
 65 70 75 80

-34-

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Ala | Val | Gly | Asp | Arg | Arg | Gln | Cys | Val | Pro | Thr | Glu | Pro | Cys | Glu |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Asp | Ala | Glu | Asp | Asp | Cys | Gly | Asn | Asp | Phe | Gln | Cys | Ser | Thr | Gly | Arg |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Cys | Ile | Lys | Met | Arg | Leu | Arg | Cys | Asn | Gly | Asp | Asn | Asp | Cys | Gly | Asp |
| | | 115 | | | | | | 120 | | | | | 125 | | |
| Phe | Ser | Asp | Glu | Asp | Asp | Cys | Glu | Ser | Glu | Pro | Arg | Pro | Pro | Cys | Arg |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Asp | Arg | Val | Val | Glu | Glu | Ser | Glu | Leu | Ala | Arg | Thr | Ala | Gly | Tyr | Gly |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Ile | Asn | Ile | Leu | Gly | Met | Asp | Pro | Leu | Ser | Thr | Pro | Phe | Asp | Asn | Glu |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Phe | Tyr | Asn | Gly | Leu | Cys | Asn | Arg | Asp | Arg | Asp | Gly | Asn | Thr | Leu | Thr |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Tyr | Tyr | Arg | Arg | Pro | Trp | Asn | Val | Ala | Ser | Leu | Ile | Tyr | Glu | Thr | Lys |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Gly | Glu | Lys | Asn | Phe | Arg | Thr | Glu | His | Tyr | Glu | Glu | Gln | Ile | Glu | Ala |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Phe | Lys | Ser | Ile | Ile | Gln | Glu | Lys | Thr | Ser | Asn | Phe | Asn | Ala | Ala | Ile |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Ser | Leu | Lys | Phe | Thr | Pro | Thr | Glu | Thr | Asn | Lys | Ala | Glu | Gln | Cys | Cys |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Glu | Glu | Thr | Ala | Ser | Ser | Ile | Ser | Leu | His | Gly | Lys | Gly | Ser | Phe | Arg |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Phe | Ser | Tyr | Ser | Lys | Asn | Glu | Thr | Tyr | Gln | Leu | Phe | Leu | Ser | Tyr | Ser |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Ser | Lys | Lys | Glu | Lys | Met | Phe | Leu | His | Val | Lys | Gly | Glu | Ile | His | Leu |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Gly | Arg | Phe | Val | Met | Arg | Asn | Arg | Asp | Val | Val | Leu | Thr | Thr | Thr | Phe |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Val | Asp | Asp | Ile | Lys | Ala | Leu | Pro | Thr | Thr | Tyr | Glu | Lys | Gly | Glu | Tyr |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| Phe | Ala | Phe | Leu | Glu | Thr | Tyr | Gly | Thr | His | Tyr | Ser | Ser | Ser | Gly | Ser |
| | | | 340 | | | | | 345 | | | | | 350 | | |
| Leu | Gly | Gly | Leu | Tyr | Glu | Leu | Ile | Tyr | Val | Leu | Asp | Lys | Ala | Ser | Met |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Lys | Arg | Lys | Gly | Val | Glu | Leu | Lys | Asp | Ile | Lys | Arg | Cys | Leu | Gly | Tyr |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| His | Leu | Asp | Val | Ser | Leu | Ala | Phe | Ser | Glu | Ile | Ser | Val | Gly | Ala | Glu |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| Phe | Asn | Lys | Asp | Asp | Cys | Val | Lys | Arg | Gly | Glu | Gly | Arg | Ala | Val | Asn |
| | | | | 405 | | | | | 410 | | | | | 415 | |
| Ile | Thr | Ser | Glu | Asn | Leu | Ile | Asp | Asp | Val | Val | Ser | Leu | Ile | Arg | Gly |
| | | | 420 | | | | | 425 | | | | | 430 | | |

-35-

Gly Thr Arg Lys Tyr Ala Phe Glu Leu Lys Glu Lys Leu Leu Arg Gly
 435 440 445

Thr Val Ile Asp Val Thr Asp Phe Val Asn Trp Ala Ser Ser Ile Asn
 450 455 460

Asp Ala Pro Val Leu Ile Ser Gln Lys Leu Ser Pro Ile Tyr Asn Leu
 465 470 475 480

Val Pro Val Lys Met Lys Asn Ala His Leu Lys Lys Gln Asn Leu Glu
 485 490 495

Arg Ala Ile Glu Asp Tyr Ile Asn Glu Phe Ser Val Arg Lys Cys His
 500 505 510

Thr Cys Gln Asn Gly Gly Thr Val Ile Leu Met Asp Gly Lys Cys Leu
 515 520 525

Cys Ala Cys Pro Phe Lys Phe Glu Gly Ile Ala Cys Glu Ile Ser Lys
 530 535 540

Gln Lys Ile Ser Glu Gly Leu Pro Ala Leu Glu Phe Pro Asn Glu Lys
 545 550 555 560

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ser Cys Trp Leu Leu
 1 5

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ala Pro Val Glu Glu Glu Asn Thr Ser Thr Phe Arg Leu Leu Pro Leu
 1 5 10 15

Lys Ile Ile Leu Ala Ala Lys
 20

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ile Ala Thr Cys Phe Met Lys Ile Leu Pro Thr Ser Glu Val Ser Ser
 1 5 10 15

Leu Leu Gly Leu
 20

-36-

- (2) INFORMATION FOR SEQ ID NO:9:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 3 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Phe Phe Phe
 1

- (2) INFORMATION FOR SEQ ID NO:10:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Phe Phe Phe Leu Lys Leu Leu
 1 5

- (2) INFORMATION FOR SEQ ID NO:11:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 51 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Cys Phe His Phe Leu Phe Pro Asn Glu Lys Ser Thr Val Lys Tyr Ala
 1 5 10 15

Arg Thr Ala Leu Ser His Gly Lys Cys Gln Ser Leu Leu Lys Lys Asn
 20 25 30

Lys Ile Lys Leu Lys Thr Glu Cys Trp Phe Lys Lys Leu Gln Arg Lys
 35 40 45

Lys Lys Lys
 50

- (2) INFORMATION FOR SEQ ID NO:12:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 561 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Leu Val Ser Ser Met Ala Ala Ser His Ser Phe Ala Phe Val Val Cys
 1 5 10 15

Val Leu Glu Ile Gly Ala Leu Thr Ala Gly Pro Thr Pro Ser Tyr Val
 20 25 30

His Glu Pro Ile Gln Arg Ser Asp Pro Leu Gln Pro Ile Asp Cys Arg
 35 40 45

Met Ser Pro Trp Ser Glu Trp Ser His Cys Asp Pro Cys Leu Arg Gln
 50 55 60

-37-

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Phe | Arg | Ser | Arg | Ser | Ile | Glu | Val | Phe | Gly | Gln | Phe | His | Gly | Lys |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Ser | Cys | Val | Asp | Ala | Leu | Gly | Asp | Arg | Arg | Ala | Cys | Ile | Pro | Thr | Glu |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Ala | Cys | Glu | Asp | Ala | Glu | Glu | Asp | Cys | Glu | Lys | Asp | Glu | Phe | His | Cys |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Gly | Thr | Gly | Arg | Cys | Ile | Lys | Arg | Arg | Leu | Leu | Cys | Asn | Gly | Asp | Asn |
| | | 115 | | | | 120 | | | | | | 125 | | | |
| Asp | Cys | Gly | Asp | Phe | Ser | Asp | Glu | Asp | Asp | Cys | Glu | Thr | Glu | Pro | Arg |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Leu | Thr | Cys | Arg | Asn | Arg | Glu | Val | Gln | Glu | Ser | Glu | Leu | Ala | Arg | Thr |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Ala | Gly | Tyr | Gly | Ile | Asn | Ile | Leu | Gly | Met | Asp | Pro | Leu | Ala | Thr | Pro |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Phe | Asp | Asn | Glu | Tyr | Tyr | His | Gly | Leu | Cys | Asp | Arg | Val | Trp | Asp | Gly |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Asn | Thr | Leu | Thr | His | Tyr | Arg | Lys | Pro | Trp | Asn | Val | Ala | Val | Leu | Ala |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Tyr | Glu | Thr | Lys | Ile | Asp | Lys | Asn | Phe | Arg | Thr | Glu | Tyr | Tyr | Glu | Glu |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Gln | Met | Gln | Ala | Phe | Lys | Ser | Ile | Ile | Glu | Glu | Glu | Thr | Ser | Asn | Phe |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Asn | Ala | Asn | Leu | Ala | Leu | Lys | Phe | Thr | Pro | Thr | Glu | Ala | Lys | Ala | Ser |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Lys | Ala | Glu | Glu | Ala | Ser | Pro | Lys | Asn | Lys | Ser | Leu | Asp | Asp | Asn | Asp |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Lys | Gly | Phe | Ser | Ser | Lys | Phe | Gln | Phe | Ser | Tyr | Ser | Lys | Asn | Glu | Thr |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Tyr | Gln | Leu | Phe | Leu | Ser | Tyr | Ser | Ser | Gln | Lys | Glu | Lys | Met | Phe | Leu |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Leu | Val | Lys | Gly | Ile | Ile | Gln | Leu | Gly | Arg | Phe | Val | Met | Lys | Asn | Arg |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Gly | Val | Met | Leu | Thr | Asn | Thr | Phe | Leu | Asp | Asp | Ile | Lys | Ser | Leu | Pro |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| Thr | Thr | Tyr | Glu | Lys | Gly | Glu | Tyr | Phe | Ala | Phe | Leu | Glu | Thr | Tyr | Gly |
| | | | 340 | | | | | 345 | | | | | 350 | | |
| Thr | His | Tyr | Ser | Ser | Ser | Gly | Ser | Leu | Gly | Gly | Arg | Tyr | Glu | Leu | Ile |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Tyr | Val | Leu | Asp | Lys | Ala | Ser | Met | Lys | Glu | Lys | Gly | Ile | Glu | Leu | Asn |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Asp | Ile | Lys | Lys | Cys | Leu | Gly | Phe | Asp | Leu | Asp | Leu | Ser | Leu | Asn | Ile |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| Pro | Gly | Lys | Ser | Ala | Gly | Leu | Ser | Leu | Thr | Gly | Gln | Ala | Asn | Lys | Asn |
| | | | | 405 | | | | | 410 | | | | | 415 | |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Asn | Cys | Leu | Lys | Ser | Gly | His | Gly | Asn | Ala | Val | Asn | Ile | Thr | Arg | Ala | |
| | | | 420 | | | | 425 | | | | | | 430 | | | |
| Asn | Leu | Ile | Asp | Asp | Val | Ile | Ser | Leu | Ile | Arg | Gly | Gly | Thr | Gln | Lys | |
| | | | 435 | | | | 440 | | | | | | 445 | | | |
| Phe | Ala | Phe | Glu | Leu | Lys | Glu | Lys | Leu | Leu | Thr | Lys | Ala | Lys | Met | Val | |
| | | | 450 | | | | 455 | | | | | | 460 | | | |
| Asp | Val | Thr | Asp | Phe | Ile | Asn | Trp | Ala | Ser | Ser | Leu | Ser | Asp | Ala | Pro | |
| | | | 465 | | | | 470 | | | | | | 475 | | | |
| Val | Leu | Ile | Asn | Gln | Lys | Leu | Ser | Pro | Ile | Tyr | Asn | Leu | Ile | Pro | Val | |
| | | | 485 | | | | | | 490 | | | | | | 495 | |
| Lys | Ile | Lys | Asp | Ala | His | Gln | Lys | Arg | Gln | Asn | Leu | Glu | Arg | Gly | Ile | |
| | | | 500 | | | | | | 505 | | | | | | 510 | |
| Glu | Asp | Tyr | Ile | Asn | Glu | Phe | Ser | Thr | Lys | Lys | Cys | Ser | Pro | Cys | Gln | |
| | | | 515 | | | | | | 520 | | | | | | 525 | |
| Asn | Gly | Gly | Thr | Ala | Leu | Leu | Met | Asp | Gly | Gln | Cys | Leu | Cys | Thr | Cys | |
| | | | 530 | | | | | | 535 | | | | | | 540 | |
| Pro | Phe | Met | Phe | Glu | Gly | Ile | Ala | Cys | Glu | Ile | Ser | Lys | Arg | Lys | Leu | |
| | | | 545 | | | | | | 555 | | | | | | 560 | |
| Ala | | | | | | | | | | | | | | | | |

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 44 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Gly Leu Pro Ala Pro Thr Pro Thr Pro Gln Asn Ala Thr Val Glu Phe
1 5 10 15

Pro Glu Leu Lys Trp Lys Lys Asn Asn Thr Arg Thr Phe Gln Cys Lys
20 25 30

Ile Leu Pro Cys Leu Glu Ile Val Leu Ala Gly Thr
35 40

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Lys Ala Thr Cys Phe Met Lys Thr Leu Pro Thr Ser Glu Ala Ser Leu
1 5 10 15
Ser Leu Trp Ser Ala Met Pro Val Phe Pro His Lys Pro Leu
20 25 30

-39-

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

~~(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:~~

Cys Phe His Phe Tyr Leu Met Lys Arg Gln Pro
1 5 10

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Ala Val Pro Glu Val Phe Ser Pro Thr Ala Asn Ala Ser Leu Leu Leu
1 5 10 15

Ile Lys Glu Asn Lys Ile Gln Lys Lys Lys Lys Lys
20 25

-40-

We claim:

1. A composition specifically modulating binding of CD59 to C9 selected from the group consisting of molecules structurally mimicking ~~C9 amino acid residues 359 to 384 which bind to CD59 and molecules~~ binding to C9 amino acid residues 359 to 384.

2. The composition of claim 1 selected from the group consisting of peptides comprising hu C9 amino acid residues 359 to 384, anti-idiotypic antibodies immunoreactive with C9 amino acid residues 359 to 384, and covalently cyclized peptides comprising hu C9 amino acid residues 359 to 384.

3. The composition of claim 2 wherein the composition is a peptide of less than forty amino acids residues including amino acid residues 359 to 384 of hu C9.

4. The composition of claim 1 selected from the group consisting of antibodies and antibody fragments immunoreactive with amino acid residues 359 to 384 of C9, peptides that bind to amino acid residues 359 to 384 of C9, and nucleotide molecules that bind to amino acid residues 359 to 384 of C9.

5. The composition of claim 1 further comprising a pharmaceutically acceptable carrier for administration to patients in need thereof.

6. A method for modulating C5b-9 complex assembly comprising administering to a patient in need thereof an effective amount of a composition to increase or prevent CD59 inhibition of C5b-9 complex assembly a composition specifically modulating binding of CD59 to C9 selected from the group consisting of molecules structurally mimicking C9 amino acid residues 359 to 384 which bind to CD59 and molecules binding to C9 amino acid residues 359 to 384.

7. The method of claim 6 selected from the group consisting of peptides comprising hu C9 amino acid residues 359 to 384, anti-idiotypic antibodies immunoreactive with C9 amino acid residues 359 to

384, and covalently cyclized peptides comprising hu C9 amino acid residues 359 to 384.

8. The method of claim 7 wherein the composition is a peptide of less than forty amino acid residues including amino acid residues 359 to 384 of hu C9.

9. The method of claim 6 selected from the group consisting of antibodies and antibody fragments immunoreactive with amino acid residues 359 to 384 of C9, peptides that bind to amino acid residues 359 to 384 of C9, and nucleotide molecules that bind to amino acid residues 359 to 384 of C9.

10. The method of claim 7 wherein the patient is in need of complement activation.

11. The method of claim 10 wherein the composition is administered as a adjunct to tumor therapy.

12. The method of claim 9 wherein the patient is in need of suppression of complement mediated inflammation.




FIGURE 1

C9

CD59 Binding Site




FIGURE 2




Figure 3

4/5




Figure 4

FIGURE 5A




FIGURE 5B




FIGURE 5C





FIGURE 5D



Concentration IgG/Fab (mg/ml)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/17940

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/17 //C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|----------------------------------------------------------------------------------------------------------|-----------------------|
| X | US 5 135 916 A (SIMS PETER J ET AL) 4 August 1992 cited in the application see claims; examples | 1-12 |
| A | WO 95 23512 A (ALEXION PHARMA INC) 8 September 1995 see claims; examples | 1-12 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

* "&" document member of the same patent family

Date of the actual completion of the international search

18 March 1997

Date of mailing of the international search report

02.04.97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Fuhr, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/17940

C.(Continuation) D CUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X | JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 8, 24 February 1995, BALTIMORE, MD US, pages 3483-3486, XP002027794 T. HUSLER ET AL.: "Chimeras of Human Complement C9 Reveal the Site Recognized by Complement Regulatory Protein CD59" see page 3485, right-hand column, paragraph 2 - page 3486, right-hand column, paragraph 2; figure 2 --- | 1-5 |
| X | JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 42, 21 October 1994, BALTIMORE, MD US, pages 26424-26430, XP002027795 C.-P. CHANG ET AL.: "Identity of a Peptide Domain of Human C9 That Is Bound by the Cell-surface Complement Inhibitor, CD59" see page 26429, left-hand column, paragraph 2 - page 26430, right-hand column, paragraph 2; figure 4 --- | 1-5 |
| P,X | BIOCHEMISTRY, vol. 35, no. 10, 12 March 1996, EASTON, PA US, pages 3263-3269, XP002027796 T. HUSLER ET AL.: "Role of a Disulfide Peptide Loop within Human Complement C9 in the Species-Selectivity of Complement Inhibitor CD59" see Results and Discussion --- | 1-5 |
| A | JOURNAL OF IMMUNOLOGY, vol. 151, no. 14, 15 August 1993, BALTIMORE US, pages 2159-2165, XP002027797 J. TSCHOPP ET AL.: "Clusterin, the Human Apolipoprotein and Complement Inhibitor, Binds to Complement C7, C8beta, and the b Domain of C9" see page 2161, right-hand column, paragraph 3 - page 2163, left-hand column, paragraph 3 --- | 1-5 |
| A | JOURNAL OF IMMUNOLOGY, vol. 152, no. 4, 15 February 1994, BALTIMORE US, pages 1927-1934, XP002027798 S. TOMLINSON ET AL.: "A Synthetic Peptide from Complement Protein C9 Binds to CD59 and Enhances Lysis of Human Erythrocytes by C5b-9" see page 1928, left-hand column, paragraph 3 ----- | 1-5 |

1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/17940

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 6-12
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 6 tot 12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/compositions.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 96/17940

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|-------------------------------------------|---------------------|----------------------------------------------|----------------------------------|
| US 5135916 A | 04-08-92 | US 5550108 A US 5573940 A | 27-08-96 12-11-96 |
| WO 9523512 A | 08-09-95 | AU 1985895 A CA 2184356 A EP 0750458 A | 18-09-95 08-09-95 02-01-97 |